
Loading, please wait...

Loading, please wait...

Managing patient anxiety effectively is a cornerstone of successful dental surgical practice. Dentists frequently utilize various pharmacological protocols to ensure patient comfort during complex procedures. Specifically, researchers recently conducted a randomized trial to evaluate the efficacy of midazolam-promethazine oral sedation compared to midazolam monotherapy. This study aimed to clarify if combining these agents provides a clinical advantage for anxious patients undergoing third molar surgery.
The randomized, double-blind, split-mouth study included eighteen patients requiring bilateral mandibular third molar extractions. During one session, patients received 15mg of midazolam alone. In a separate session, they received a combination of 15mg of midazolam and 25mg of promethazine. Surprisingly, the depth of sedation, measured by the Ramsay scale, showed no statistically significant difference between the two protocols. Similarly, both groups reported comparable anxiety levels based on the Corah scale throughout the procedures. Consequently, these results suggest that midazolam alone remains a highly effective standard for moderate sedation.
Beyond sedation depth and anxiety control, the trial monitored crucial physiological parameters. Researchers observed that Group B experienced slight variations in heart rate and oxygen saturation at specific time intervals. However, these changes remained well within safe clinical limits and did not lead to adverse complications. Because the clinical benefits of the combination were not superior, the study highlights that midazolam monotherapy might be sufficient for most routine extractions. Therefore, clinicians should weigh the necessity of additional agents against the potential for altered physiological responses.
According to this randomized clinical trial, the combination of midazolam and promethazine does not significantly improve the depth of sedation or reduce patient anxiety compared to using midazolam alone for third molar extractions.
The combination therapy showed minor, statistically significant fluctuations in heart rate and oxygen saturation. Nevertheless, these changes were not clinically dangerous, and both sedation protocols were considered safe for healthy patients in this study.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A randomized trial comparing oral midazolam and midazolam-promethazine for third molar surgery finds no significant difference in sedation depth or anxiety....
6 months ago

Co-administering antiseizure medications and DOACs frequently causes pharmacokinetic interactions, subtherapeutic drug levels, and thromboembolic failures. This review highlights enzyme induction risks, unpredictable outcomes with levetiracetam, and the vital role of therapeutic drug monitoring.
Today

Demanding exhaustive hormonal profiling can inadvertently discourage clinical studies involving females. Methodological standards must align with the specific scientific question to expand, not restrict, equitable evidence for women.
Today

An elderly man with partially repaired Tetralogy of Fallot presented with STEMI caused by coronary embolism rather than atherosclerosis. Successful treatment with sustained mechanical aspiration thrombectomy underscores the vital need for high clinical vigilance in adult congenital heart disease.
Today

A comparative review of tension band wiring and intramedullary screw fixation in thumb metacarpophalangeal arthrodesis, evaluating union rates, hardware complications, and clinical outcomes.
Today

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today